<DOC>
	<DOCNO>NCT00545909</DOCNO>
	<brief_summary>This 2 arm study assess impact Bone Marker Feedback ( BMF ) , use blood sample communication result 2 month , adherence monthly Bonviva ( 150mg po ) woman post-menopausal osteoporosis . Patients randomize either 1 ) group receive bone marker feedback 2 ) group receive feedback result . The study also assess patient satisfaction treatment monthly Bonviva . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>BEATRIS Study : A Study Adherence Bonviva ( Ibandronate ) Once Monthly Women With Post-Menopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>ambulatory postmenopausal woman osteoporosis ; 5585 year age ; eligible bisphosphonate treatment ; naive bisphosphonate therapy , lapse user ( last bisphosphonate intake &gt; 6 month ago ) . inability stand sit upright position least 60 minute ; inability swallow tablet whole ; hypersensitivity bisphosphonates ; administration drug , presence active disease , know influence bone metabolism ; uncorrected hypocalcemia bone disturbances bone mineral metabolism ; history major upper gastrointestinal disease .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>